URGN
UroGen Pharma LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.41B
P/E Ratio
—
EPS
$-2.74
Beta
1.59
52W High
$32.37
52W Low
$3.60
50-Day MA
$22.89
200-Day MA
$21.22
Dividend Yield
—
Profit Margin
-94.80%
Forward P/E
—
PEG Ratio
0.00
About UroGen Pharma Ltd
UroGen Pharma Ltd (URGN) is a pioneering biotechnology company dedicated to advancing treatment options for urological diseases, particularly urothelial carcinoma and bladder cancer. Utilizing its proprietary reverse thermal gel platform, UroGen facilitates targeted and sustained local drug delivery, enhancing therapeutic effectiveness while minimizing systemic adverse effects. With a robust clinical pipeline aimed at addressing significant unmet medical needs, UroGen is well-positioned to transform patient care and solidify its leadership role in the urological oncology market.
Fundamentals
| Revenue (TTM) | $140.49M |
| Gross Profit (TTM) | $126.24M |
| EBITDA | $-107.90M |
| Operating Margin | -39.80% |
| Return on Equity | -1481.00% |
| Return on Assets | -27.00% |
| Revenue/Share (TTM) | $2.88 |
| Book Value | $-2.18 |
| Price-to-Book | 19.27 |
| Price-to-Sales (TTM) | 10.02 |
| EV/Revenue | 10.4 |
| EV/EBITDA | -2.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 151.60% |
| Shares Outstanding | $48.72M |
| Float | $43.18M |
| % Insiders | 3.64% |
| % Institutions | 99.44% |
Historical Volatility
HV 10-Day
68.05%
HV 20-Day
71.38%
HV 30-Day
73.78%
HV 60-Day
70.56%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($36.44 target)
1
Strong Buy6
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026